Search

Your search keyword '"Trent, Jeffrey M"' showing total 1,064 results

Search Constraints

Start Over You searched for: Author "Trent, Jeffrey M" Remove constraint Author: "Trent, Jeffrey M"
1,064 results on '"Trent, Jeffrey M"'

Search Results

51. Supplemental Tables S1-S12 from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion

52. Supplementary Table S1 from HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases

53. Tables S1 to S13 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma

54. Supplementary Figures and Methods from HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases

55. Figure S2 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma

56. Figure S3 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type

57. Figures S1-3 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition

58. Table S2 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition

59. Supplementary Legend from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma

60. Figure S6 from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion

61. Figure S1 from Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma

63. Supplemental Methods from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition

65. Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion

66. Supplementary Methods from Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma

67. Table S5-6 from Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition

68. Data from HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases

69. Supplementary Figure S3 from Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells

70. Supplementary Materials and Methods from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis

71. Supplementary Tables 1-3 from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis

72. Data from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis

73. Supplementary Figure 1 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen

74. Supplementary Data 4 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen

75. Supplementary Data 3 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen

76. Supplementary Figures 1-2 from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis

77. Supplementary Data 2 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen

78. Supplementary Data 1 from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen

79. Data from Integrating Global Gene Expression and Radiation Survival Parameters across the 60 Cell Lines of the National Cancer Institute Anticancer Drug Screen

82. Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search

83. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2

84. Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer

85. Abstract C039: Influence of patient ancestry on homologous recombination repair deficiency in cancer

86. Abstract A006: Increased germline mutational burden in individuals of African ancestry: Implications for interpretation of tumor mutation burden

87. Cancer Genomics and Evolution

89. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients

90. Abstract 2013: Integrated proteomic analysis identifies four distinct subtypes of high-risk neuroblastoma

91. Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity.

93. A Framework for Promoting Diversity, Equity, and Inclusion in Genetics and Genomics Research

94. A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma

95. Advancing a clinically relevant perspective of the clonal nature of cancer

98. Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma

100. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.

Catalog

Books, media, physical & digital resources